

- Küpfer A and Branch RA (1985) Stereo selective mephobarbital hydroxylation co-segregates with mephenytoin hydroxylation. *Clin Pharmacol Ther* **38**:414–418.
- Nielsen KK, Brøsen K, Hansen J and Gram LF (1994) Single-dose kinetics of clomipramine: relationship to the sparteine/debrisoquine and *S*-mephenytoin oxidation polymorphisms. *Clin Pharmacol Ther* **55**:518–527.
- Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. *J Biol Chem* **239**:2370–2378.
- Richardson TH, Jung F, Griffin KJ, Wester M, Raucy JL, Kemper B, Bornheim LM, Hassett C, Omiecinski CJ and Johnson EF (1995) A universal approach to the expression of human and rabbit cytochrome P450 of the 2C subfamily in *Escherichia coli*. *Arch Biochem Biophys* **323**:87–96.
- Romkes M, Faletto MB, Blaisdell J, Raucy JL and Goldstein JA (1991) Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. *Biochemistry* **30**:3247–3255.
- Sarich T, Kalhorn T, Magee S, Al-Sayegh F, Adams S, Slattery J, Goldstein J, Nelson S and Wright J (1997) The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of *S*-mephenytoin. *Clin Pharm Ther* **62**:21–28.
- Sindrup SH, Brøsen K, Hansen MGJ, Aaes-Jorgensen T, Overo KF and Gram LF (1993) Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. *Ther Drug Monit* **13**:11–17.
- Skjelbo E, Brøsen K, Hallas J and Gram LF (1991) The mephenytoin oxidative polymorphism is partially responsible for the *N*-demethylation of imipramine. *Clin Pharmacol Ther* **49**:18–23.
- Tartof KD and Hobbs CA (1987) Improved media for growing plasmid and cosmid clones. *Bethesda Res Lab Focus* **9**:19.
- Ward SA, Walle T, Walle UK, Wilkinson GR and Branch RA (1989) Propranolol's metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities. *Clin Pharmacol Ther* **45**:72–79.
- Ward SA, Helsby NA, Skejlbø E, Brøsen K, Gram LF and Breckenridge AM (1991) The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. *Br J Clin Pharmacol* **31**:689–692.
- Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA and Wilkinson GR (1984) Direct enantiomeric resolution of mephenytoin and its *N*-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. *J Chromatogr B Biomed Appl* **307**:121–127.
- Wedlund PJ, Sweetman BJ, Wilkinson GR and Branch RA (1987) Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of *S*-mephenytoin in man. *Drug Metab Dispos* **15**:277–279.
- Wilkinson GR, Guengerich FP and Branch RA (1989) Genetic polymorphism of *S*-mephenytoin hydroxylation. *Pharmacol Ther* **43**:53–76.
- Wrighton SA, Stevens JC, Becker GW and VandenBranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and *S*-mephenytoin 4'-hydroxylation. *Arch Biochem Biophys* **306**:240–245.
- Xiao ZS, Goldstein JA, Xie H-G, Blaisdell J, Wang W, Jiang C-H, Yan F-X, He N, Huang S-L, Xu Z-H and Zhou H-H (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the *S*-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. *J Pharmacol Exper Ther* **281**:604–609.
- Zhang Y, Blouin RA, McNamara PJ, Steinmetz J and Wedlund PJ (1992) Limitation to the use of urinary *S/R* mephenytoin ratio in pharmacogenetic studies. *Br J Clin Pharmacol* **31**:350–352.

Send reprint requests to: Joyce Blaisdell (C3–01), NIEHS, P.O. Box 12233, Room C324, 111 Alexander Drive, Research Triangle Park, NC 27709. E-mail: Blaisde1@NIEHS.NIH.GOV

ERRATUM

T. Tuntland, A. Odinecs, C. Nosbisch and J. D. Unadkat (1998): *In Vivo* Maternal-Fetal-Amniotic Fluid Pharmacokinetics of Zisovudine in the Pigtailed Macaque: Comparison of Steady-State and Single-Dose Regimens, JPET Vol. **285**(1):54–62.

The publisher regrets that Table 4 (Antipyrine clearances and volumes of distribution) on page 59 was incorrectly labeled as Table 2 (Zidovudine clearances and volumes of distribution). The data for this table were presented accurately.